Compare Vanguard Emerging Markets Stock Index Fund ETF (VWO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Emerging Markets Stock Index Fund ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Emerging Markets Stock Index Fund ETF trades at $59.76 (market cap $168.50B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 83.4× GeneDx Holdings Corp's market cap, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Emerging Markets Stock Index Fund ETF for 135 Days and GeneDx Holdings Corp for 19 Days on average.
| VWO | WGS | |
|---|---|---|
Market Cap | $168.50B | $2.02B |
Volume | 9,650,999 | 734,640 |
52-Week High | $61.44 | $167.51 |
52-Week Low | $52.42 | $34.51 |
Typical Hold Time | 135 Days | 19 Days |
Sector | — | Health |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VWO trades at $59.10, down 1.25% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as AI-driven Taiwan exposure provides strength while China's economic slowdown weighs on performance. Recent institutional buying by Allianz and Alamar Capital contrasts with technical weakness.
The emerging markets ETF offers diversification but faces headwinds from China's property and consumer weakness. Technical indicators suggest caution near-term, though institutional accumulation and AI infrastructure demand provide potential catalysts for patient investors.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
